Eisai Co., Ltd. to Present Data on Lenvima® Monotherapy and in Combination with Keytruda® (Pembrolizumab) in Multiple Cancer Types
January 11, 2021 at 01:08 pm
Share
Eisai Co., Ltd. will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021. Investigational data on the lenvatinib plus pembrolizumab combination that will be presented includes results from the Phase 2 LEAP-005 trial (NCT03797326) evaluating multiple cohorts of patients with previously treated solid tumors, including: gastric cancer (Abstract #230), biliary tract cancers (Abstract #321) and colorectal cancer (Abstract #94). Additional data to be presented include findings from a post-hoc analysis in patients with unresectable hepatocellular carcinoma (HCC) who progressed to Child-Pugh B liver function in the Phase 3 REFLECT trial (NCT01761266) evaluating lenvatinib (Abstract #298). Also, real-world effectiveness of lenvatinib monotherapy among unresectable HCC patients in the United States clinical practices will be presented (Abstract #273). In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck's anti-PD-1 therapy pembrolizumab. To date, 20 trials have been initiated under the LEAP (LEnvatinib And Pembrolizumab) clinical program, which is evaluating the combination across 13 different tumor types.
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).